Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)
Standard
Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3). / Tran, Ben; Ruiz-Morales, Jose M; Gonzalez-Billalabeitia, Enrique; Patrikidou, Anna; Amir, Eitan; Seidel, Christoph; Bokemeyer, Carsten; Fankhauser, Christian; Hermanns, Thomas; Rumyantsev, Alexey; Tryakin, Alexey; Brito, Margarida; Fléchon, Aude; Kwan, Edmond Michael; Cheng, Tina; Castellano, Daniel; Garcia Del Muro, Xavier; Hamid, Anis A; Ottaviano, Margaret; Palmieri, Giovannella; Kitson, Robert; Reid, Alison; Heng, Daniel Y C; Bedard, Philippe L.
in: CANCER MED-US, Jahrgang 9, Nr. 1, 01.2020, S. 116-124.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Large retroperitoneal lymphadenopathy and increased risk of venous thromboembolism in patients receiving first-line chemotherapy for metastatic germ cell tumors: A study by the global germ cell cancer group (G3)
AU - Tran, Ben
AU - Ruiz-Morales, Jose M
AU - Gonzalez-Billalabeitia, Enrique
AU - Patrikidou, Anna
AU - Amir, Eitan
AU - Seidel, Christoph
AU - Bokemeyer, Carsten
AU - Fankhauser, Christian
AU - Hermanns, Thomas
AU - Rumyantsev, Alexey
AU - Tryakin, Alexey
AU - Brito, Margarida
AU - Fléchon, Aude
AU - Kwan, Edmond Michael
AU - Cheng, Tina
AU - Castellano, Daniel
AU - Garcia Del Muro, Xavier
AU - Hamid, Anis A
AU - Ottaviano, Margaret
AU - Palmieri, Giovannella
AU - Kitson, Robert
AU - Reid, Alison
AU - Heng, Daniel Y C
AU - Bedard, Philippe L
N1 - © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
PY - 2020/1
Y1 - 2020/1
N2 - BACKGROUND: Metastatic germ cell tumor (mGCT) patients receiving chemotherapy have increased risk of life-threatening venous thromboembolism (VTE). Identifying VTE risk factors may guide thromboprophylaxis in this highly curable population.METHODS: Data were collected from mGCT patients receiving first-line platinum-based chemotherapy at 22 centers. Predefined variables included International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification, long-axis diameter of largest retroperitoneal lymph node (RPLN), Khorana score, and use of indwelling vascular access device (VAD). VTE occurring at baseline, during chemotherapy and within 90 days, was analyzed.RESULTS: Data from 1135 patients were collected. Median age was 31 years (range 10-74). IGCCCG risk was 64% good, 20% intermediate, and 16% poor. VTE occurred in 150 (13%) patients. RPLN >3.5 cm demonstrated highest discriminatory accuracy for VTE (AUC 0.632, P < .001) and was associated with significantly higher risk of VTE in univariable analysis (22% vs 8%, OR 3.0, P < .001) and multivariable analysis (OR 1.8, P = .02). Other significant risk factors included, Khorana score ≥3 (OR 2.6, P = .008) and VAD use (OR 2.7, P < .001).CONCLUSIONS: Large RPLN and VAD use are independent risk factors for VTE in mGCT patients receiving chemotherapy. VAD use should be minimized in this population and thromboprophylaxis might be considered for large RPLN.
AB - BACKGROUND: Metastatic germ cell tumor (mGCT) patients receiving chemotherapy have increased risk of life-threatening venous thromboembolism (VTE). Identifying VTE risk factors may guide thromboprophylaxis in this highly curable population.METHODS: Data were collected from mGCT patients receiving first-line platinum-based chemotherapy at 22 centers. Predefined variables included International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification, long-axis diameter of largest retroperitoneal lymph node (RPLN), Khorana score, and use of indwelling vascular access device (VAD). VTE occurring at baseline, during chemotherapy and within 90 days, was analyzed.RESULTS: Data from 1135 patients were collected. Median age was 31 years (range 10-74). IGCCCG risk was 64% good, 20% intermediate, and 16% poor. VTE occurred in 150 (13%) patients. RPLN >3.5 cm demonstrated highest discriminatory accuracy for VTE (AUC 0.632, P < .001) and was associated with significantly higher risk of VTE in univariable analysis (22% vs 8%, OR 3.0, P < .001) and multivariable analysis (OR 1.8, P = .02). Other significant risk factors included, Khorana score ≥3 (OR 2.6, P = .008) and VAD use (OR 2.7, P < .001).CONCLUSIONS: Large RPLN and VAD use are independent risk factors for VTE in mGCT patients receiving chemotherapy. VAD use should be minimized in this population and thromboprophylaxis might be considered for large RPLN.
U2 - 10.1002/cam4.2674
DO - 10.1002/cam4.2674
M3 - SCORING: Journal article
C2 - 31715650
VL - 9
SP - 116
EP - 124
JO - CANCER MED-US
JF - CANCER MED-US
SN - 2045-7634
IS - 1
ER -
